VERIGRAFT
VERIGRAFT generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous-like (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression.
VERIGRAFT has raised €1.2M across 1 funding round from 1 investor, most recently a Grant round in Feb 2025. Based in Gothenburg, Sweden; active in Healthtech. Data as of 28 Oct 2026.
Gothenburg, Swedenverigraft.com ↗
Total raised
€1.2M
€1,200,000
Funding rounds
1
Investors
1
distinct backers
Active since
2025-02
latest 2025-02
Funding by year
EUR raised per yearVERIGRAFT — funding by year — interactive chart.
Data table
| VERIGRAFT — funding by year | |
|---|---|
| 2025 | €1.2M |
Signals
High confidenceRaise-next likelihood16
base rate 45% for Grant
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-02-14 | Grant | €1.2M | EuroStars | View deal → |